Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial to Assess the Efficacy, Safety and Tolerability of Cenerimod in Adult Patients With Systemic Lupus Erythematosus and Active Lupus Nephritis in Combination With Background Therapy

NCT07201129 is registered in ClinicalTrials.gov with Viatris Innovation GmbH as lead sponsor.

NCT NCT07201129
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07201129 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial to Assess the Efficacy, Safety and Tolerability of Cenerimod in Adult Patients With Systemic Lupus Erythematosus and Active Lupus Nephritis in Combination With Background Therapy
Lead sponsor
Viatris Innovation GmbH
Phase
Phase 3
Overall status
Recruiting
Start date
February 9, 2026
Completion date
February 28, 2030
Enrollment
300 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

lupus erythematosus, systemic, nephritis, lupus